|Source||Humanized (from mouse)|
|14px (what is this?)|
Tigatuzumab (CS-1008) is a monoclonal antibody for the treatment of cancer. As of October 2009[update], a clinical trial for the treatment of pancreatic cancer has been completed, Phase II trials for colorectal cancer and non-small cell lung cancer are running, and a study for ovarian cancer has been approved.
The drug targets member 10b of the tumor necrosis factor receptor superfamily (TNFRSF10B, better known as death receptor 5 or trail receptor 2), a protein overexpressed in many kinds of tumour.
A recent study reports on the preclinical validation of 111In-labeled anti-DR5 humanised antibody CS-1008 as a diagnostic tool to study the DR5 occupancy in cancer patients, and establish dose ranges for receptor saturation kinetics in vivo.
- WHO Drug Information
- NCI: Combination Therapy Targets Pancreatic Cancer Stem Cells
- NCI: CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin
- NCI: CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)
- NCI: Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer
- NCI: CS-1008
Lua error in package.lua at line 80: module 'Module:Buffer' not found. Lua error in package.lua at line 80: module 'Module:Buffer' not found.